Showing 8,641 - 8,660 results of 18,392 for search 'significant ((((a decrease) OR (((we decrease) OR (nn decrease))))) OR (mean decrease))', query time: 0.53s Refine Results
  1. 8641
  2. 8642

    Multi-State Redox and Light-Driven Switching of Pseudorotaxanation and Cation Shuttling by Robert Hein (4849108)

    Published 2025
    “…Specifically, the neutral switches can be quantitatively converted between <i>anti-</i> and <i>syn-</i>folded receptor geometries by irradiation, leading to the discovery of a significant increase or decrease in cation binding affinity, which was exploited to shuttle the pseudorotaxane-forming dibenzylammonium guest between the switchable crown ethers of slightly different sizes. …”
  3. 8643

    Image 1_A study on pregenomic RNA and factors in the pregnant and postpartum women with chronic HBV infection based on real world.jpeg by Juan Tang (437969)

    Published 2025
    “…</p>Methods<p>A total of 134 pregnant and 100 postpartum CHB patients were enrolled, and serum pgRNA levels were quantified.…”
  4. 8644

    Table 1_A study on pregenomic RNA and factors in the pregnant and postpartum women with chronic HBV infection based on real world.docx by Juan Tang (437969)

    Published 2025
    “…</p>Methods<p>A total of 134 pregnant and 100 postpartum CHB patients were enrolled, and serum pgRNA levels were quantified.…”
  5. 8645

    Table 1_Cancer-associated fibroblasts gene signature: a novel approach to survival prediction and immunotherapy guidance in colon cancer.docx by Wenbing Zhang (152972)

    Published 2025
    “…The nomogram further effectively predicted the prognosis of COAD patients, with low-risk patients having a better prognosis. A higher immune infiltration rate and lower IC50 values of anticancer drugs were significant in the high-risk group. …”
  6. 8646

    Supplementary Material for: Association between serum albumin to creatinine ratio and readmission in elderly heart failure patients: A Retrospective Cohort Study by Guo L. (3722611)

    Published 2024
    “…After adjusting for potential confounders, we found that for each unit increase in sACR, the 28-day readmission rate decreased by 48% (OR = 0.52, 95% CI: 0.29-0.95, P = 0.003). …”
  7. 8647

    Table 2_Cancer-associated fibroblasts gene signature: a novel approach to survival prediction and immunotherapy guidance in colon cancer.xlsx by Wenbing Zhang (152972)

    Published 2025
    “…The nomogram further effectively predicted the prognosis of COAD patients, with low-risk patients having a better prognosis. A higher immune infiltration rate and lower IC50 values of anticancer drugs were significant in the high-risk group. …”
  8. 8648

    Image 1_Cancer-associated fibroblasts gene signature: a novel approach to survival prediction and immunotherapy guidance in colon cancer.tif by Wenbing Zhang (152972)

    Published 2025
    “…The nomogram further effectively predicted the prognosis of COAD patients, with low-risk patients having a better prognosis. A higher immune infiltration rate and lower IC50 values of anticancer drugs were significant in the high-risk group. …”
  9. 8649

    <b>Feature-based molecular networking of two Arenga species extracts, appraisal of their anti-inflammatory, analgesic and antidiarrheal activity</b>: Raw data (LC-MS/MS) by Wafaa A. Ahmed (21667440)

    Published 2025
    “…Also, it decreased the gastrointestinal motility in charcoal meal protocol and a showed an inhibitory effect on gastrointestinal motility with all investigated doses. …”
  10. 8650

    Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  11. 8651

    Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  12. 8652

    Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  13. 8653

    Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  14. 8654

    Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  15. 8655

    Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  16. 8656

    Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  17. 8657

    Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  18. 8658

    Suppl. Figure 1, García-Ortuño, et al. by NORMA A. Bobadilla (22642043)

    Published 2025
    “…<p dir="ltr">During gestation period, all pregnant rats showed a significant increase in BW from day 15 onward, however, in the CC and CR groups, this increase was already evident from the day 10. …”
  19. 8659

    Table 1_The role of gut microbiota in modulating immune responses in chronic liver disease: a systematic review and meta-analysis.docx by Eyad Gadour (21375983)

    Published 2025
    “…The findings revealed that gut microbiota-modulating therapies significantly reduced tumor necrosis factor-α (TNF-α) levels compared to control interventions (standardized mean difference [SMD], -0.60; 95% confidence interval [CI] [-0.93, -0.23] p = 0.001), with similar results observed at the 6-month follow-up (SMD -1.3; 95% CI [-2.1, -0.4] p = 0.004). …”
  20. 8660

    Table 1_The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.docx by Jingjing Zhou (179820)

    Published 2025
    “…Meta-analysis results demonstrated that danuglipron significantly decreased HbA1c (mean difference [MD]: −0.90; 95% CI: −1.06, −0.74), FPG (MD: −24.66; 95% CI: −30.45, −18.86) and weight (MD: −2.17; 95% CI: −3.10, −1.23) and improved FPI (MD: 2.94; 95% CI: 1.50, 4.38). …”